UA115555C2 - Склад лаквінімоду без засобів для підлуговування та зменшення окиснення - Google Patents

Склад лаквінімоду без засобів для підлуговування та зменшення окиснення Download PDF

Info

Publication number
UA115555C2
UA115555C2 UAA201413984A UAA201413984A UA115555C2 UA 115555 C2 UA115555 C2 UA 115555C2 UA A201413984 A UAA201413984 A UA A201413984A UA A201413984 A UAA201413984 A UA A201413984A UA 115555 C2 UA115555 C2 UA 115555C2
Authority
UA
Ukraine
Prior art keywords
laquinimod
pharmaceutical composition
stable pharmaceutical
lubricant
contain
Prior art date
Application number
UAA201413984A
Other languages
English (en)
Ukrainian (uk)
Inventor
Гаді Сарфаті
Іоана Ловінгер
Даніт Ліхт
Мухаммад Сафаді
Original Assignee
Тева Фармасьютікл Індастріз Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тева Фармасьютікл Індастріз Лтд. filed Critical Тева Фармасьютікл Індастріз Лтд.
Publication of UA115555C2 publication Critical patent/UA115555C2/uk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47042-Quinolinones, e.g. carbostyril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
UAA201413984A 2012-07-11 2013-10-07 Склад лаквінімоду без засобів для підлуговування та зменшення окиснення UA115555C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261670268P 2012-07-11 2012-07-11
PCT/US2013/049894 WO2014011750A1 (en) 2012-07-11 2013-07-10 Laquinimod formulations without alkalizing agent

Publications (1)

Publication Number Publication Date
UA115555C2 true UA115555C2 (uk) 2017-11-27

Family

ID=49914501

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201413984A UA115555C2 (uk) 2012-07-11 2013-10-07 Склад лаквінімоду без засобів для підлуговування та зменшення окиснення

Country Status (19)

Country Link
US (1) US20140018386A1 (https=)
EP (1) EP2872141A4 (https=)
JP (1) JP2015527321A (https=)
KR (1) KR20150036553A (https=)
CN (1) CN104470519A (https=)
AR (1) AR091706A1 (https=)
AU (1) AU2013290274A1 (https=)
BR (1) BR112015000321A2 (https=)
CA (1) CA2873230A1 (https=)
EA (1) EA201590193A1 (https=)
HK (1) HK1209054A1 (https=)
IL (1) IL236229A0 (https=)
MX (1) MX2015000398A (https=)
NZ (1) NZ630241A (https=)
SG (2) SG10201700198VA (https=)
TW (1) TW201408299A (https=)
UA (1) UA115555C2 (https=)
WO (1) WO2014011750A1 (https=)
ZA (1) ZA201500287B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2445451T3 (es) 2007-12-20 2014-03-03 Teva Pharmaceutical Industries, Ltd. Preparaciones estables de laquinimod
CN106063787A (zh) 2012-02-03 2016-11-02 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療gaba媒介之疾病之拉喹莫德(laquinimod)
JP2015535287A (ja) 2012-11-07 2015-12-10 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドのアミン塩
NZ630427A (en) 2013-03-14 2017-06-30 Teva Pharma Crystals of laquinimod sodium and improved process for the manufacture thereof
EA201692180A1 (ru) 2014-04-29 2017-08-31 Тева Фармасьютикал Индастриз Лтд. Лахинимод для лечения пациентов с рецидивирующе-ремиттирующим рассеянным склерозом (рррс) с высоким статусом инвалидизации
CN107823168A (zh) * 2017-10-25 2018-03-23 北京素维生物科技有限公司 一种快速溶解的片剂及其制备方法
CN107823150A (zh) * 2017-10-25 2018-03-23 北京素维生物科技有限公司 一种可快速分散的片剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
SE0400235D0 (sv) * 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
US7884208B2 (en) * 2005-10-19 2011-02-08 Teva Pharmaceutical Industries, Ltd. Crystals of laquinimod sodium, and process for the manufacture thereof
RS52169B (sr) * 2006-06-12 2012-08-31 Teva Pharmaceutical Industries Limited Stabilni preparati lakvinimoda
ES2445451T3 (es) * 2007-12-20 2014-03-03 Teva Pharmaceutical Industries, Ltd. Preparaciones estables de laquinimod
WO2010070449A2 (en) * 2008-12-17 2010-06-24 Actavis Group Ptc Ehf Highly pure laquinimod or a pharmaceutically acceptable salt thereof
WO2013016686A1 (en) * 2011-07-28 2013-01-31 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and interferon-beta

Also Published As

Publication number Publication date
NZ630241A (en) 2017-09-29
ZA201500287B (en) 2016-10-26
EA201590193A1 (ru) 2015-04-30
TW201408299A (zh) 2014-03-01
IL236229A0 (en) 2015-01-29
US20140018386A1 (en) 2014-01-16
EP2872141A4 (en) 2016-01-13
BR112015000321A2 (pt) 2017-06-27
SG11201407688QA (en) 2014-12-30
WO2014011750A1 (en) 2014-01-16
JP2015527321A (ja) 2015-09-17
EP2872141A1 (en) 2015-05-20
HK1209054A1 (zh) 2016-03-24
AR091706A1 (es) 2015-02-25
WO2014011750A8 (en) 2014-12-04
MX2015000398A (es) 2015-04-10
SG10201700198VA (en) 2017-02-27
AU2013290274A1 (en) 2014-11-27
KR20150036553A (ko) 2015-04-07
CN104470519A (zh) 2015-03-25
CA2873230A1 (en) 2014-01-16

Similar Documents

Publication Publication Date Title
UA115555C2 (uk) Склад лаквінімоду без засобів для підлуговування та зменшення окиснення
CA2715760C (en) Solid preparation for oral administration of cariprazine hydrochloride
JP2010518822A (ja) ビタミンおよびミネラル補助食品における改善された安定性
US10603280B2 (en) Active ingredient containing stabilised solid medicinal forms and methods for the production thereof
UA78500C2 (en) Amlodipine maleate pharmaceutical composition
WO2006135638A2 (en) Tanaproget compositions containing ethinyl estradiol
ES2319193T3 (es) Formulacion farmaceutica que comprende levotiroxina sodica.
ES2706067T3 (es) Una composición farmacéutica que contiene candesartán cilexetilo y amlodipino
MXPA03006625A (es) Proceso para preparar composiciones no higroscopica de valproato de sodio.
WO2015022559A1 (en) Pharmaceutical composition containing rosuvastatin and ramipril
KR102044734B1 (ko) 캡슐 제형
WO2021250204A1 (en) Oral formulation comprising a crystalline form of rabeximod
RU2240784C1 (ru) Лекарственное средство на основе арбидола
KR20140001648A (ko) 안정성이 개선된 클로피도그렐 황산수소염의 경구용 제제 제품
KR20150036228A (ko) 향상된 분산성을 갖는 약학적 조성물, 약물 및 이의 제조 및 사용방법
EA027787B1 (ru) Пероральные лекарственные формы, содержащие лерканидипин и эналаприл и их фармацевтически приемлемые соли
CA3011685C (en) Stable trientine formulations
WO2020254396A1 (en) Solid pharmaceutical dosage form comprising spray dried vitamin b12
RU2248205C1 (ru) Лекарственное средство в виде желатиновой капсулы
RU2174836C1 (ru) Фармацевтическая композиция, обладающая анальгезирующим действием
CZ21666U1 (cs) Stabilní kompozice pregabalinu
SI21062A2 (sl) Farmacevtski sestavki, ki obsegajo amlodipin maleat